Leerink Partnrs Has Positive Estimate for PepGen Q1 Earnings

PepGen Inc. (NASDAQ:PEPG) – Equities researchers at Leerink Partnrs increased their Q1 2025 earnings estimates for shares of PepGen in a research note issued on Monday, February 24th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.75) per share for the quarter, up from their prior forecast of ($0.76). The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for PepGen’s Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.21) EPS and FY2026 earnings at ($2.93) EPS.

Other analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of PepGen in a research note on Monday. Bank of America cut shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a research report on Monday, December 16th. Finally, Wedbush cut their price objective on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, November 8th.

PepGen Trading Down 25.3 %

PEPG opened at $1.71 on Wednesday. The company has a market capitalization of $55.75 million, a price-to-earnings ratio of -0.57 and a beta of 1.53. PepGen has a 12-month low of $1.16 and a 12-month high of $19.30. The business’s fifty day simple moving average is $2.46 and its 200-day simple moving average is $5.78.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.13.

Institutional Investors Weigh In On PepGen

A number of institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC purchased a new stake in shares of PepGen during the third quarter valued at about $95,000. Suvretta Capital Management LLC raised its stake in shares of PepGen by 9.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after acquiring an additional 140,000 shares in the last quarter. Walleye Capital LLC purchased a new stake in PepGen during the third quarter valued at approximately $519,000. Janus Henderson Group PLC boosted its stake in PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after acquiring an additional 1,794,641 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in PepGen by 76.9% in the third quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock worth $346,000 after purchasing an additional 17,618 shares during the last quarter. Institutional investors own 58.01% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.